Health · Medical Research · 1 hr ago
Expert panel identifies non-hormonal options for menopause symptoms
An international panel from the European Society of Gynecology reviewed evidence on non-hormonal ways to manage menopause symptoms for women who cannot or do not want to use hormone therapy.
The panel said neurokinin receptor antagonists have the strongest evidence among non-hormonal medicines for hot flashes and night sweats.
In clinical trials, fezolinetant reduced hot-flash and night-sweat frequency by about 63% after 12 weeks, while elinzanetant reduced it by 65% to 67% in two trials; placebo groups also saw reductions.
The panel described healthy eating, exercise, weight management and good sleep habits as the foundation of care.
Psychological therapies and treatments aimed at genitourinary symptoms, such as vaginal dryness or urinary discomfort, are also options.
Hormone therapy remains the most effective treatment for hot flashes and night sweats, but some medical conditions make it unsuitable, and some women prefer alternatives.
No direct trials compared the newer medicines with hormone therapy, and the statement offers evidence-based guidance rather than a new treatment or trial.
An international expert panel from the European Society of Gynecology identified non-hormonal options for menopause symptoms in a consensus statement.
The panel found that neurokinin receptor antagonists have the strongest evidence among non-hormonal medicines for hot flashes and night sweats.
The statement also lists lifestyle changes, psychological therapies and targeted treatments for genitourinary symptoms as options.
The recommendations are aimed at women who cannot use menopausal hormone therapy or prefer not to use it.
- Who
- An international expert panel from the European Society of Gynecology.
- What
- It reviewed evidence on non-hormonal treatments for menopause symptoms and issued a consensus statement.
- When
- The statement was described as recent; the article was published on 2026-11-20.
- Where
- The statement was published in the journal Gynecological Endocrinology.
- Why
- To provide evidence-based recommendations for women with medical contraindications to hormone therapy or who prefer not to use it.
This story does not have two clearly opposing sides.
In clinical trials, fezolinetant reduced vasomotor symptom frequency by approximately 63%, compared with 40% for placebo.
Fezolinetant maintained its efficacy.
- Expert body
- European Society of Gynecology
- Journal
- Gynecological Endocrinology
- Fezolinetant
- Approximately 63% reduction in symptom frequency after 12 weeks, compared with 40% for placebo
- Elinzanetant
- 65% to 67% reduction in symptom frequency in two phase 3 trials, compared with 42% to 46% for placebo
- Source article date
- 2026-11-20